MAPT and Alzheimer disease: Neuropathological assessment data of the end-of-life study included Bielschowsky silver stain (BSS) Standard of Truth, Aβ phase [7], Consortium for the Establishment of a Registry for Alzheimer’s Disease (CERAD) score [23], Braak staging for tau pathology [24], the National Institute on Aging (NIA) and Ronald and Nancy Reagan Institute (NIA-RI) score [25], and the NIA-Alzheimer’s Association (NIA-AA) ABC score [8] for AD likelihood.